Zacks Research Has Negative Estimate for MMSI Q1 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Zacks Research reduced their Q1 2025 earnings per share (EPS) estimates for Merit Medical Systems in a research report issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will earn $0.76 per share for the quarter, down from their previous forecast of $0.81. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.37 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q2 2025 earnings at $0.96 EPS, Q4 2025 earnings at $1.02 EPS, Q1 2026 earnings at $0.74 EPS, Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $1.10 EPS, Q4 2026 earnings at $1.15 EPS and FY2027 earnings at $4.34 EPS.

A number of other research analysts have also recently commented on MMSI. Piper Sandler reissued an “overweight” rating and issued a $116.00 target price (up previously from $114.00) on shares of Merit Medical Systems in a report on Wednesday, January 29th. Barrington Research cut their target price on shares of Merit Medical Systems from $115.00 to $111.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Canaccord Genuity Group decreased their target price on shares of Merit Medical Systems from $128.00 to $127.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. Wells Fargo & Company dropped their price target on Merit Medical Systems from $120.00 to $117.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reduced their price objective on Merit Medical Systems from $122.00 to $116.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.78.

Merit Medical Systems Price Performance

Shares of MMSI stock opened at $101.68 on Thursday. The business has a fifty day simple moving average of $103.93 and a 200 day simple moving average of $100.75. The company has a market cap of $5.98 billion, a P/E ratio of 49.84, a P/E/G ratio of 2.34 and a beta of 0.91. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. Merit Medical Systems has a twelve month low of $70.70 and a twelve month high of $111.45.

Insider Buying and Selling at Merit Medical Systems

In other Merit Medical Systems news, insider Brian G. Lloyd sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $102.90, for a total transaction of $3,087,000.00. Following the completion of the transaction, the insider now owns 38,945 shares in the company, valued at approximately $4,007,440.50. This trade represents a 43.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen C. Evans sold 5,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $105.31, for a total transaction of $526,550.00. Following the completion of the sale, the director now directly owns 4,657 shares in the company, valued at approximately $490,428.67. This represents a 51.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,132 shares of company stock worth $11,139,521. Insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Peak Retirement Planning Inc. acquired a new position in shares of Merit Medical Systems in the 4th quarter valued at about $875,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Merit Medical Systems by 17.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,344 shares of the medical instruments supplier’s stock worth $15,992,000 after purchasing an additional 24,528 shares in the last quarter. iSAM Funds UK Ltd acquired a new position in Merit Medical Systems in the fourth quarter valued at approximately $424,000. Virtus Investment Advisers Inc. boosted its holdings in shares of Merit Medical Systems by 45.7% during the 4th quarter. Virtus Investment Advisers Inc. now owns 11,192 shares of the medical instruments supplier’s stock worth $1,082,000 after buying an additional 3,513 shares in the last quarter. Finally, Tidal Investments LLC grew its position in shares of Merit Medical Systems by 3,197.9% during the 4th quarter. Tidal Investments LLC now owns 342,912 shares of the medical instruments supplier’s stock worth $33,166,000 after buying an additional 332,514 shares during the period. Institutional investors and hedge funds own 99.66% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.